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ABSTRACT Modification of the surface of distearoyl phos-
phatidylcholine vesicles with synthetic glycolipids dramatically
affects the rate of uptake of these vesicles by mouse peritoneal
macrophage. The high rate of uptake of 6-aminomannose-modi-
fied vesicles is effectively inhibited by cytochalasin B and chloro-
quine but not by colchicine, indicating that the mechanism of ves-
icle uptake is phagocytosis. Other modified vesicles appear to have
some effect on the rate of uptake of 6-aminomannose-modified
vesicles suggesting that the various vesicle types compete for the
same initial binding sites. Analysis of 6-aminomannose-modified
vesicles by y-ray perturbed angular correlation spectroscopy
shows that the rotational correlation time of the encapsulated
"'In3' does not change when the vesicles associate with macro-
phage. This result is consistent with transmission electron mi-
croscopy, which indicates that the aminomannose-modified vesi-
cles remain intact after phagocytosis as aggregates of fused and
intact vesicles surrounded by a single bilayer membrane structure.
There is a growing body of evidence that carbohydrate cell-sur,
face determinants play a significant role in intercellular recog-
nition processes. Examples of mammalian carbohydrate rec-
ognition systems include (i) the receptor for galactose-terminated
glycoproteins found in hepatocytes (1, 2), (ii) the receptor for
6-phosphomannosyl-containing glycoproteins found in fibro-
blasts (3, 4), and (iii) the receptor for mannose-terminated gly-
coproteins found in macrophage and polymorphonuclear leu-
kocytes of the reticuloendothelial system (5-7). The existence
of these receptors suggests that it should be possible to control
the tissue distribution and cellular uptake of phospholipid ves-
icles by attaching appropriate carbohydrate determinants to the
vesicle surface (8-11).
The modification of the surface of distearoyl phosphatidyl-
choline vesicles with particular synthetic glycolipids has been
shown to affect dramatically the tissue distribution and stability
ofthese vesicles in mice (12, 13). The use ofvesicles loaded with
"'In enables the structural integrity of the vesicles to be de-
termined in vivo by y-ray perturbed angular correlation (PAC)
spectroscopy and the tissue distribution to be determined by
standard gamma-counting techniques (14-16). After intrave-
nous injection, vesicles modified with 6-aminomannose deriv-
atives of cholesterol produced initial retention ofhigh levels of
intact vesicles in the lung, followed by concentration of intact
vesicles in the liver and spleen. These modified vesicles con-
centrated in the axillary spaces associated with aggregates of
polymorphonuclear leukocytes and macrophage when admin-
istered subcutaneously.
The unusual tissue distributions and long-lifetimes observed
in vivo for aminomannose-modified vesicles must depend in a
complex way on interactions of these vesicles with serum com-
ponents and specific cell types. To establish a better basis for
understanding the remarkably stereospecific mechanisms for
recognition and transport of carbohydrate-modified phospho-
lipid vesicles in vivo, it is essential to study the interaction of
such modified vesicles with various isolated cell types. In this
paper we report measurements of the kinetics of uptake of sur-
face-modified vesicles by mouse peritoneal macrophage.
MATERIALS AND METHODS
L-a-Distearoyl phosphatidylcholine (Ste2-PtdCho) from Calbi-
ochem and cholesterol from Sigma were used without further
purification. Fucosyl, glucosyl, galactosyl, xylosyl, mannosyl,
aminomannosyl, and glucuronic acid derivatives of cholesterol*
were gifts from Merck Sharp & Dohme (10). Dicetyl phosphate
and stearylamine were purchased from Sigma, the trisodium
salt of nitrilotriacetic acid was from Aldrich and ultrapure InCl3
was from Ventron (Danvers, MA). [oleate-l-'4C]Cholestervl
oleate with specific activity of 51 Ci/mol (1 Ci = 3.7 x 10Wo
becquerels) was purchased from New England Nuclear. Car-
rier-free "'1InCl3 was purchased from Medi+Physics (Glen-
dale, CA) and purified according to the method of Hwang and
Mauk (14). The ionophore A23187 was a gift from Eli Lilly.
Newborn calf serum, medium-199, and penicillin/strep-
tomycin were purchased from Microbiological Associates (Los
Angeles, CA). Cytochalasin B, colchicine, and chloroquine
were purchased from Sigma. Ferritin (cationized) also was pur-
chased from Sigma.
Preparation of Liposomes. Small unilamellar vesicles were
prepared by the method of Mauk and coworkers (14-16). For
most ofthe in vitro phagocytosis studies, [I4C]cholesteryl oleate
was included in the lipid mixture as a marker. Total phospho-
lipid was determined by phosphorus assay as described (17).
The effect of temperature on the permeability of vesicles con-
taining "'In3+ was monitored by PAC spectroscopy (14-16).
Cultivation of Mouse Peritoneal Mononuclear Phagocytes.
Cells from the peritoneal cavity of unstimulated male
Swiss-Webster mice (25-30 g) were harvested by the method
of Steinman and Cohn (18). A suspension of 4.2 X 106 cells
[42 tkg of protein by microassay (19)] was plated to a plastic
petri dish, and the adhered monolayer of macrophage (1.3-1.6
x 10' cells)-free oflymphocytes was maintained for 24 hr before
Abbreviations: PAC, y-ray perturbed angular correlation; Ste2-PtdCho,
L-a-distearoyl phosphatidylcholine; Pam2-PtdCho, L-a-dipalmitoyl
phosphatidylcholine.
*6-(5-cholesten-33-yloxy)hexyl 1-thio-3-D-glucopyranoside; 6-(5-cho-
lesten-3,-yloxy)hexyl 1-thio-f3-L-fucopyranoside; 6-(5-cholesten-3f-
yloxy)hexyl 1-thio-nD-galactopyranoside; 6-(5-cholesten-3,-yloxy)hexyl
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use 'with 0.2 ml of medium 199 containing 20% (vol/vol) new-
born calf serum and penicillin/streptomycin (500 units/ml).
Measurement of Phagocytosis. Freshly prepared liposomes
were added to the petri dish culture to an activity of about
15,000 cpm (-30 A.l or -16.5 Ag ofphosphorus), and phagocy-
tosis was permitted to proceed at 370C or at temperatures as
otherwise specified. At selected time intervals, the tissue cul-
ture medium was aspirated, and monolayers were rinsed with
-.saline.three times to remove unattached liposomes. Then 0.5
ml of 0.1% trypsin in saline was added to the monolayer petri
dish culture and incubated at 370C for 10 min. Cells of the
monolayer suspension were scraped off the petri dish carefully
with a rubber policeman and pipetted into a scintillation count-
ing vial to a final volume of 1.5-ml with the addition of two 0.5-
ml washes. The viability of the macrophage, which was deter-
mined by 0.05% trypan blue, was greater than 96%. The count-
ing vials were briefly sonicated in a bath sonicator (Laboratory
Supply, Hicksville, NY) before the addition of20 ml ofAquasol.
A Beckman LS-350 liquid scintillation counter with an average
counting efficiency of65% was used to assay for '4Cradioactivity.
Inhibition Assay. This assay was performed by the method
of Axile and Reaven (20). Cytochalasin B freshly prepared as a
stock solution of 1 mM in dimethyl sulfoxide was added to a petri
dish containing tissue culture medium at the concentrations
specified in Results. Macrophage cells were incubated with li-
posomes for 2 hr in this modified medium. The tissue culture
medium was then aspirated, and monolayers were rinsed three
times with saline. Phagocytosis was measured as described
above. Stock solutions of 1 mM colchicine and chloroquine were
freshly -prepared in 0.9% NaCl/5 mM sodium phosphate, pH
7.4. Colchicine solution was used the same way as cytochalasin
B. Chloroquine was added 15 min before the addition of
vesicles.
Competition Assay. '4C-Labeled liposomes were first mixed
with cold (unlabeled) liposomes and were then added to a petri
dish containing culture medium and macrophage. After 2 hr of
incubation at 370C, phagocytosis was measured as described
above. The % (wt/wt) of 14C-labeled and unlabeled liposomes
was obtained by phosphorus assay of both labeled and cold
liposomes.
Electron Microscopic Study. After in vitro cultivation, both
untreated macrophage and macrophage that had been exposed
to aminomannose-substituted liposomes were prepared for
electron microscopy. In some cases, ferritin particles were en-
capsulated in the aminomannose liposomes during sonication
before they were added to the macrophage culture. Macro-
phage monolayers were rinsed three times with saline and then
were fixed for 1 hr in 2.5% (vol/vol) glutaraldehyde containing
0.1 M cacodylate buffer (pH 7.4 at room temperature). Mono-
layers were rinsed with saline and postfixed again with 2.5%
glutaraldehyde in 0.1 M cacodylate buffer at 40C. Monolayers
were dehydrated in graded alcohol and embedded in Epon-812.
Sections were cut with LKB Ultrotome III and picked up on
an uncoated grid. The transmission electron microscopy was
carried out by D. A. Golde and S. Poolsawat at the UCLA
School of Medicine.
RESULTS
Vesicle Integrity. Because phospholipid vesicles with various
surface modifications have potentially very important applica-
tions as vehicles for the delivery of pharmacologically active
agents, it is important to understand what factors influence their
integrity in the presence of serum. Leakage of entrapped "'In
from vesicles in the presence ofserum can be monitored by the
PAC technique because complexation of "'In3+ with high mo-
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FIG. 1. Effect of cholesterol content on transition temperature for
permeability ofvesicles to "'In3". The percentage of"'In3+ originally
encapsulated that remains after incubation for 0.5 hr in the presence
ofserum as determined by the PAC method isplotted vs. the incubation
temperature for various mole ratios of Ste2-PtdCho:choles-
terol:aminomannose. x, (2.0:0.5:0.5); n, (2.1:0.4:0.5); *, (2.25:0.25:
0.5); 0, (2.5:0.0:0.5).
lecular weight serum components results in a decrease in the
rotational correlation time of the "'In3". The percentage of
"'In which remained encapsulated at various fixed tempera-
tures in the presence of serum is shown in Fig. 1 for Ste2-
PtdCho vesicle compositions that differ in.cholesterol content.
Both the transition temperature for "'In leakage and the width
of the transition region depended on cholesterol composition.
The width of the transition region for "'In leakage appeared to
be influenced by the presence of cholesterol substituted with
aminomannose.
The effect ofphospholipid composition on the leakage of"'In
from vesicles is shown in Fig. 2. For vesicles containing only
Ste2-PtdCho and cholesterol, the temperature at which half of
the "'In remains encapsulated by the PAC criterion was about
80TC. Because the entire transition region is well above phys-
iological temperature, this 'vesicle composition was used for in
vivo studies in mice (12, 13) and for the macrophage-uptake
studies reported here. The transition temperature for 1'In leak-
age was strongly dependent on the phospholipid composition
(Fig. 2). The transition range for "'In leakage could be adjusted
to physiological temperatures by mixing various amounts of L-
a-dipalmitoyl phosphatidylcholine (Pam2-PtdCho) with Ste2-
PtdCho .and cholesterol. Regulation of the release of vesicle
contents is an important element in any strategy for the use of
vesicle systems for the delivery of pharmacologically-active
agents (21).
Interaction of Vesicles with Mouse Peritoneal Macrophage.
The uptake of Ste2-PtdCho by mouse peritoneal macrophage
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FIG. 2. Effect of phospholipid composition on transition tempera-
ture for'permeability of vesicles to lllIn3 . The percentage of " In'
originally encapsulated that remains after incubation for 0.5 hr in the
presence ofserum as determined'by the PAC-method is plotted vs. the
incubation temperature for various mole ratios ofPam2-PtdCho: Ste2-
PtdCho:cholesterol:aminomannose. x, (0.0:2.0:0.5:0.5); A, (0.5:1.5:0.5:
0.5); o, (1.0:1.0:0.5:0.5); o, (1.5:0.5:0.5:0.5).
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FIG. 3. Uptake ofvarious modified phospholipid vesicles by mouse
peritoneal macrophage at 3700 as a function ofincubation time. o and
A, Aminomannose-modified vesicles; *, stearylamine-, dicetylphos-
phate-, glucose-, glucuronic acid-, galactose-, xylose-, fucose-, and man-
nose-modified vesicles and unmodified Ste2-PtdCho/cholesterol vesicles.
for various vesicle compositions as measured by the `4C activity
remaining with the cells is shown in Fig. 3. Aminomannose-
modified vesicles showed a substantial rate of uptake (7.7 jig
per 106 cells) for about 4 hr. The rate of uptake for the other
vesicle systems studied was too small to determine with the
same concentration of 14C label used for the aminomannose sys-
tem. The rate ofuptake ofaminomannose-modified vesicles was
linear in the cell population. Analysis of aminomannose-modi-
fled vesicles by the PAC method indicated that the rotational
correlation time of encapsulated "'In3' does not change when
the vesicles associate with macrophage. The temperature de-
pendence of the rate of uptake of aminomannose-modified ves-
icles yielded an Arrhenius plot giving an activation energy of
12.6 Kcal/mol above a transition temperature of 17TC.
Inhibition of Vesicle Uptake. The rate of vesicle uptake by
macrophage was reduced by using cytochalasin B, colchicine,
and chloroquine (Fig. 4). Cytochalasin B was clearly the most
effective inhibitor, whereas chloroquine and colchicine had less
effect at comparable concentrations.
The rate of uptake of aminomannose-modified vesicles was
also affected by competition with various other vesicle systems
(Fig. 5). The competition of unlabeled aminomannose vesicles
with 14C-labeled vesicles gave a line of unit slope, as would be
expected. Other modified vesicles (freshly prepared) appeared
to have some effect on the rate ofaminomannose vesicle uptake,
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FIG. 4. Effect of various inhibitors on the rate of uptake of ami-
nomannose-modified phospholipid vesicles by mouse peritoneal mac-
rophage at 3700. A, Cytochalasin B; x, colchicine; o, chloroquine.
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FIG. 5. Effect of various unlabeled (cold) vesicle types on the rate
ofuptake of14C-labeled aminomannose-modified phospholipid vesicles
by mouse peritoneal macrophage at 370C. e, Unlabeled aminoman-
nose-modified vesicles; x, unlabeled mannose-modified vesicles; A,
unlabeled stearylamine-modified vesicles; o, unlabeled, unmodified
Ste2-PtdCho/cholesterol vesicles.
suggesting that the various vesicle types compete for the same
binding sites. Yeast mannan dissolved in the medium at con-
centrations from 1 to 3 mg/ml inhibited the rate of aminoman-
nose vesicle uptake by 8-12%.
Transmission Electron Microscopy. Transmission electron
micrographs showing the interaction of aminomannose-modi-
fied vesicles with macrophage are seen in Fig. 6. An unactivated
macrophage cell is shown in Fig. 6a while a similar cell after
a 4-hr incubation with aminomannose-modified vesicles is
shown in Fig. 6b. There is evident formation of vacuoles and
aggregates at higher magnification, which appear to consist of
fused and intact vesicles and broken membrane fragments sur-
rounded by a single bilayer membrane structure as shown in
Fig. 6c. The encapsulated ferritin particles can also be seen in-
side individual vacuoles.
DISCUSSION
The permeability of phospholipid vesicles to '11In3+ is clearly
strongly dependent on vesicle composition (Figs. 1 and 2). Re-
ducing the cholesterol content or replacing Ste2-PtdCho with
Pam2-PtdCho reduces the transition temperature determined
by the PAC method. It is important that the vesicle permeabil-
ity is measured in the presence ofserum in this assay to provide
a better approximation to the conditions expected in vivo. A
variety ofserum components have been shown to bind to vesicle
membranes (22), and the transition temperature determined by
the PAC method is significantly reduced for vesicles in the pres-
ence of serum.
The rate of uptake of small unilamellar vesicles composed of
Ste2-PtdCho and cholesterol modified with aminomannose is
much greater than the rate ofuptake for any ofthe other vesicle
systems studied (Fig. 3). It has been proposed that negatively-
charged vesicles composed of phospholipids that are fluid at
37TC are taken up by cells by fusion, whereas negatively-
charged solid vesicles and neutral fluid and solid vesicles are
taken up predominantly by endocytosis (23). It also has been
suggested that positively-charged fluid vesicles are taken up by
endocytosis (24). The observation that cytochalasin B effectively
inhibits aminomannose-modified vesicle uptake indicates that
the uptake mechanism for these vesicles is endocytosis (20).
Compounds such as colchicine generally are not expected to
inhibit endocytosis (25, 26). Thus, the results for colchicine (Fig.
3) are also consistent with the conclusion that endocytosis is the
predominant mechanism of aminomannose-modified vesicle
uptake. It has been suggested that chloroquine inhibits recep-
tor-mediated ligand uptake by macrophage and fibroblasts (27,
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FIG. 6. Transmission electron micrographs showing the interaction ofmouse peritoneal macrophage with aminomannose-modified phospholipid
vesicles containing lead-coupled ferritin as a marker. (a) Unactivated macrophage cell in the absence ofvesicles. (b) Macrophage cell after incubation
for 4 hr in the presence of aminomannose-modified vesicles. (c) Higher-magnification image of an aggregate of vesicles internalized in the mac-
rophage cell.
28). The observation that chloroquine also inhibits aminoman-
nose-modified vesicle uptake indicates that endocytosis may
occur through a receptor-mediated process.
The temperature dependence of the rate of uptake of ami-
nomannose-modified vesicles by macrophage is also consistent
with endocytosis. Silverstein et al. (29) have argued that phago-
cytosis does not proceed unless the temperature of incubation
exceeds some critical threshold of about 18-21TC. For pino-
cytosis, there appears to be no critical thermal transition, and
an activation energy of 17.6 kcal/mol is observed for solute
uptake in mouse fibroblasts (30).
The extraordinarily high rate of uptake of aminomannose-
modified vesicles is apparently not simply due to charge effects
because neither positively-charged vesicles (modified with
stearylamine) nor negatively-charged vesicles (modified with
dicetyl phosphate or glucuronic acid) show measurable uptake
under the conditions ofthese experiments. The observation that
unmodified vesicles and vesicles modified with mannose or
stearylamine are about equally effective in competing with the
uptake of '4C-labeled aminomannose-modified vesicles indi-
cates that the initial binding steps must not depend on the ste-
reochemistry of aminomannose. This is also consistent with the
observation that mannan weakly inhibits aminomannose vesicle
uptake. However, the rates of reaction steps in the endocytosis
mechanism that follow the initial binding of vesicles to mac-
rophage could be very sensitive to the binding constant for the
aminomannose determinant with receptors on the macrophage
cell surface. The mechanics of the endocytosis process will cer-
tainly depend on the (i) magnitude of binding constants for spe-
cific determinants with receptors, (ii) concentration of deter-
minants and receptors per unit area of vesicle and cell surface,
(iii) mobility of determinants and receptors in the vesicle cell
membranes, (iv) the flexibility ofthe vesicle and cell membrane,
and (v) the size of the vesicle.
The existence of receptor activity for D-mannose has been
demonstrated for rat and mouse alveolar macrophage (31, 32)
and for human polymorphonuclear leukocytes (33). However,
the rate of uptake by mouse peritoneal macrophage of amino-
mannose vesicles is much greater than the rate of uptake of
mannose vesicles. Ryser and Shen (34) have shown that metho-
trexate conjugated to polylysine (which contains a large number
of amino groups) is rapidly taken up by tumor cells in culture.
Although the mechanism of this process has not yet been es-
tablished, it is possible that the rapid endocytosis observed for
aminomannose-modified vesicles is simply dependent on the
presence of large numbers of amino groups per unit area ex-
tending well beyond the vesicle surface region.
PAC studies of the uptake by macrophage ofaminomannose-
modified vesicles containing "'1In3+ provide the interesting re-
sult that the vesicles remain intact after endocytosis. This ex-
perimental result may be related to our previous observation
that aminomannose-modified vesicles remain intact for about
600 hr in vivo in mice after subcutaneous injection (12). It is
important to understand why the integrity of the aminoman-
nose-labeled vesicles is not destroyed by the lysosomal ma-
chinery of the macrophage. This may be simply related to the
robust vesicle composition used in these experiments or to the
effective pH of the vesicle surface after endocytosis.
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In the absence of serum factors, mouse alveolar macrophage
are still capable ofbinding yeast cells (32). Mannose is the major
soluble component ofthe yeast cell wall. When serum is omitted
from the incubator medium, mouse peritoneal macrophage re-
tain 75% of the uptake activity for aminomannose vesicles ob-
served when serum is present in the incubation medium. This
result indicates that serum is not a critical factor for endocytosis
of these vesicles.
The exchange of cell membrane-bound cholesterol with ex-
ogenous synthetic glycolipids (35) and with cholesterol con-
tained in lipid vesicles (36) has been reported. Because there
was no measurable uptake of '4C activity from freshly-prepared
vesicles composed of Ste2-PtdCho and cholesterol except when
the vesicles were modified with aminomannose, it seems un-
likely that exchange of the 14C label is a serious complication
in these measurements. For the Ste2-PtdCho/cholesterol ves-
icles used in these experiments, the exchange of ["4C]cholesterol
oleate with macrophage membrane-bound cholesterol is prob-
ably negligible during the 1-2 hr incubation periods that usually
were used.
The unusual effects of vesicle surface modification with ami-
nomannose provide potentially powerful approaches to a better
understanding of the details of carbohydrate-determinant rec-
ognition and the mechanisms of endocytosis, lysis, and recep-
tor-protein recycling in phagocytic cells. However, the re-
markably large rate of endocytosis of aminomannose-modified
vesicles by macrophage also suggests some interesting appli-
cations. For example, Fidler (37) has shown that phospholipid
vesicles can be used to deliver macrophage activation factor to
macrophage in vivo and that macrophage thus activated are
effective in reducing metastic tumors. The use of aminoman-
nose-modified vesicles might substantially improve this ap-
proach. Other examples of potentially interesting applications
include treatment ofleishmaniasis (38, 39) and Gaucher disease
(40) and enhancement of the production of interferon (41, 42).
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